Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Omeros

Omeros?uq=UG6efJS6
1994 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
OMER STOCK SYMBOL
2 INVESTMENTS
$15.45 SHARE PRICE (As of Wednesday Closing)
Description

Operator of a biopharmaceutical company intended to discover, develop, and commercialize small-molecule and protein therapeutics. The company's biopharmaceutical services focuses on inflammation and disorders of the central nervous system which is a proprietary platform that delivers low-dose combinations of therapeutic agents directly surgical sites throughout the duration of the procedures, as a means to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.

Website
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 201 Elliott Avenue West
  • Seattle, WA 98119
  • United States

+1 (206) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Omeros’s full profile, request a free trial.

Omeros Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$9.00 - $26.69 $746M $15.37 -$1.82 823K 48.6M

Omeros Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 888,764 929,046 448,764 591,935
Revenue 38,661 64,826 41,617 13,509
EBITDA (74,891) (41,900) (58,626) (71,314)
Net Income (87,783) (53,481) (66,745) (75,096)
Total Assets 106,349 116,328 67,278 48,995
Total Debt 130,358 84,607 79,710 49,842
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Omeros Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Omeros‘s full profile, request access.

Request full access to PitchBook

Omeros Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 (0000 000 23-Nov-2010 000000000000000000 000.00 Biotechnology 0000000 000000000 00
Nura 07-Sep-2006 Merger/Acquisition 00000 Drug Discovery 0000000 000000000 00
To view this company’s complete investment and acquisition history, request access »

Omeros Executive Team (14)

Name Title Board
Seat
Contact
Info
Gregory Demopulos MD Founder, President, Chief Executive Officer & Chairman
Richard Klein Chief Financial Officer
Michael Jacobsen Chief Accounting Officer, Treasurer & Vice President, Finance
George Gaitanaris Ph.D Chief Scientific Officer & Vice President, Science
Leonard Blum Chief Business and Commercial Officer

2 Former Executives

You’re viewing 5 of 14 executives. Get the full list »

Omeros Board Members (7)

Name Representing Role Since Contact
Info
000000 000000 Omeros Chairman of Audit Committee 000 0000
00000 0000 00.0 Self Board Member 000 0000
00000 000000000 00 Omeros Board Member 000 0000
00000 0000 00 Self Board Member 000 0000
000 000000 Omeros Board Member & Member of Audit Committees 000 0000

2 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »